Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director | May 05, 2020 | May 06, 2020 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | Director | April 27, 2021 | April 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyra Therapeutics, Inc.
Report date May 05, 2020 · Filed May 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,064 |
Reported balance
After 2020-05-05 transaction · row 1
1 source rowRow 1 · 2020-05-05 · Conversion · Acquired 6,404 · Balance 55,064 |
| Series A-1/A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-05 · Conversion · Disposed 97,216 · Balance 0 F1: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. |
| Series A-1/B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-05 · Conversion · Disposed 55,991 · Balance 0 F1: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. |
| Series A-1/C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-05-05 · Conversion · Disposed 67,672 · Balance 0 F1: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering.
Theravance Biopharma, Inc.
Report date April 27, 2021 · Filed April 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,828 |
Reported balance
After 2021-04-27 transaction · row 1
1 source rowRow 1 · 2021-04-27 · Grant · Acquired 9,828 · Balance 9,828 |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.35 · Expires 2031-04-26 | Direct | 6,000 |
Reported balance
After 2021-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-27 · Grant · Acquired 6,000 · Balance 6,000 F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Family Trust | 27,650 |
Reported balance
Holding disclosure · report date 2021-04-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 27,650 |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 211,598 |
Reported balance
Holding disclosure · report date 2021-04-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 211,598 |
Filing footnotes · ownership attribution and instrument terms
F1: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2021 Filed Apr 29, 2021 18:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $20.35 | $0.00 |
DisclosureSEC source: 0001179110-21-004703 · edgar.xml · derivative · entry 4 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004703 · edgar.xml · nonDerivative · entry 1 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,828 Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:34 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/C Convertible Preferred Stock · Derivative | 67,672 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012177 · doc4.xml · derivative · entry 4 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:34 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/B Convertible Preferred Stock · Derivative | 55,991 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012177 · doc4.xml · derivative · entry 3 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:34 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/A Convertible Preferred Stock · Derivative | 97,216 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012177 · doc4.xml · derivative · entry 2 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,819 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:34 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 6,404 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012177 · doc4.xml · nonDerivative · entry 1 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 1, 2020 18:35 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantCommon Stock | 19,661 | $16.00 | $314,576.00 |
DisclosureSEC source: 0000899243-20-011746 · doc4.xml · nonDerivative · entry 1 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,660 Read SEC document |
| April 30, 2020 Filed May 1, 2020 18:35 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 14,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011746 · doc4.xml · derivative · entry 2 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option vests and becomes exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 21:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $30.14 | $0.00 |
DisclosureSEC source: 0001179110-20-005323 · edgar.xml · derivative · entry 4 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2030-04-27 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 21:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005323 · edgar.xml · nonDerivative · entry 1 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 Read SEC document |
| April 30, 2019 Filed May 2, 2019 18:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001179110-19-005469 · edgar.xml · derivative · entry 4 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2029-04-29 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 30, 2019 Filed May 2, 2019 18:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005469 · edgar.xml · nonDerivative · entry 1 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,963 Read SEC document |
| January 02, 2019 Filed May 2, 2019 18:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 21,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005469 · edgar.xml · nonDerivative · entry 2 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 27,650 Read SEC document |
| May 01, 2018 Filed May 3, 2018 18:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $24.43 | $0.00 |
DisclosureSEC source: 0001179110-18-006196 · edgar.xml · derivative · entry 4 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| May 01, 2018 Filed May 3, 2018 18:20 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 8,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006196 · edgar.xml · nonDerivative · entry 1 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,578 Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 20:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | PurchaseOrdinary Shares | 4,000 | $24.69 | $98,764.00 |
DisclosureSEC source: 0001179110-17-011479 · edgar.xml · nonDerivative · entry 1 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 4,000 Read SEC document |
| May 17, 2017 Filed May 18, 2017 18:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007546 · edgar.xml · nonDerivative · entry 1 WHITESIDES GEORGE M · CIK 0001233438 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,392 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.